Advanced Imaging in Prostate Cancer Management: Current Status and Future Perspectives

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 5212

Special Issue Editors

Research Department, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong SAR, China
Interests: MRI; MR-guided radiotherapy; medical imaging

E-Mail
Guest Editor
Comprehensive Oncology Centre, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong SAR, China
Interests: MR-guided radiotherapy; prostate cancer; radiation oncology

E-Mail Website
Guest Editor
Department of Surgery, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
Interests: urology; prostate cancer; surgery

E-Mail
Guest Editor
Department of Nuclear Medicine and Positron Emission Tomography, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong SAR, China
Interests: PET; nuclear medicine

E-Mail
Guest Editor
Department of Diagnostic & Interventional Radiology, Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong SAR, China
Interests: mpMRI; diagnosis

Special Issue Information

Dear Colleagues, 

Advanced imaging has been playing an increasingly important role in the management of prostate cancer (PCa). For instance, multi-parametric MRI (mpRI) defined in The Prostate Imaging-Reporting and Data System (PI-RADS) is a novel promising tool for the diagnosis of prostate cancer that might help to reduce overdiagnosis of insignificant prostate cancer. mpMRI-targeted and PSMA-targeted PET biopsies are both known to have increased the detection rate and diagnostic accuracy of clinically significant prostate cancer. Together, they improve risk stratification and help in the selection of low-risk PC patients for active surveillance. Individually, mpMRI is effective in T staging by assessment of peri-prostatic tumor infiltration while PSMA-PET is useful in the evaluation of lymph node (N-staging) and distant metastasis (M-staging). The emerging utility of integrated PET/MRI is gaining importance as a multi-modality approach in the comprehensive management of PCa.

Besides diagnosis, MRI and PET have also recently contributed to the advancement of therapeutics for PCa, such as in radiation therapy, focal ablative therapy, and surgery. MRI-aided or MRI-only radiotherapy treatment planning has been increasingly adopted in routine clinical practice, while its utilization has yet to be standardized. MRI-guided adaptive radiotherapy (MRgART) empowered by the introduction of MRI-integrated linear accelerators (MR-LINAC) represents an innovative PC treatment technique, which hopefully will further improve treatment outcomes and reduce toxicities. On the other hand, PSMA-PET has gained a definitive role in the management of biochemical recurrence after primary cancer treatment and early identification of oligometastatic disease which is most critical in determining the chance of cure by either salvage radiotherapy or salvage lymph node dissection. Recent advancements in radiomics and artificial intelligence are also facilitating imaging markers in combination with other biomarkers in PCa management.

This Special Issue aims at providing a comprehensive picture of this lively research area by gathering contributions covering all aspects related to the use of advanced imaging in PCa management. We encourage the submissions of both original and review articles, including but not limited to technical, experimental, translational, and clinical studies. 

Dr. Jing Yuan
Dr. Darren M. C. Poon
Dr. Peter Ka-Fung Chiu
Dr. Garrett Chi Lai Ho
Dr. Gladys Goh Lo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

 

Keywords

  • mpMRI
  • PET
  • prostate cancer
  • diagnosis
  • prognosis
  • treatment response
  • precision medicine
  • imaging biomarkers
  • artificial intelligence
  • radiomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 3071 KiB  
Article
Comparative Performance of 68Ga-PSMA-11 PET/CT and Conventional Imaging in the Primary Staging of High-Risk Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
by Guido Rovera, Serena Grimaldi, Marco Oderda, Giancarlo Marra, Giorgio Calleris, Giuseppe Carlo Iorio, Marta Falco, Cristiano Grossi, Roberto Passera, Giuseppe Campidonico, Maria Luce Mangia, Désirée Deandreis, Riccardo Faletti, Umberto Ricardi, Paolo Gontero and Silvia Morbelli
Diagnostics 2024, 14(17), 1964; https://doi.org/10.3390/diagnostics14171964 - 5 Sep 2024
Viewed by 822
Abstract
This prospective study aimed to (1) compare the diagnostic performance of 68Ga-PSMA-11 PET/CT with respect to conventional imaging (computed tomography (CT) and bone scintigraphy (BS)) in the primary staging of high-risk prostate cancer (PCa) patients and (2) validate PSMA-PET/CT accuracy in pelvic [...] Read more.
This prospective study aimed to (1) compare the diagnostic performance of 68Ga-PSMA-11 PET/CT with respect to conventional imaging (computed tomography (CT) and bone scintigraphy (BS)) in the primary staging of high-risk prostate cancer (PCa) patients and (2) validate PSMA-PET/CT accuracy in pelvic nodal staging in comparison with postoperative histopathology and assess PSMA-PET/CT’s impact on patient management. Sixty castration-sensitive high-risk (ISUP 4–5 and/or PSA > 20 ng/mL and/or cT3) PCa patients eligible for radical prostatectomy were enrolled (median PSA 10.10 [IQR: 6.22–17.95] ng/mL). PSMA-PET/CT, compared with CT, identified nodal (N) and/or distant metastases (M1) in 56.7% (34/60) vs. 13.3% (8/60) (p < 0.001) of patients: N + 45% vs. 13.3% (p < 0.001), M1a 11.7% vs. 1.7% (p = 0.03), M1b 23.3% vs. 1.7% (p < 0.001). Compared with BS, PSMA-PET/CT localized unknown skeletal metastases in 15% (9/60) of cases, with no false negative findings. Overall, PSMA-PET/CT led to a TNM upstaging in 45.0% (27/60) of cases, with no evidence of downstaging, resulting in a change in management in up to 28.8% (17/59) of patients. Compared with histopathology data (n = 32 patients), the per-patient accuracy of PSMA-PET/TC for detecting pelvic nodal metastases was 90.6%. Overall, the above evidence supports the use of PSMA-PET/CT in the diagnostic workup of high-risk prostate cancer staging. Full article
Show Figures

Figure 1

13 pages, 3466 KiB  
Article
Evaluation of the Reliability and the Performance of Magnetic Resonance Imaging Radiomics in the Presence of Randomly Generated Irrelevant Features for Prostate Cancer
by Cindy Xue, Jing Yuan, Gladys G. Lo, Darren M. C. Poon and Winnie C. W. Chu
Diagnostics 2023, 13(23), 3580; https://doi.org/10.3390/diagnostics13233580 - 1 Dec 2023
Cited by 1 | Viewed by 1266
Abstract
Radiomics has the potential to aid prostate cancer (PC) diagnoses and prediction by analyzing and modeling quantitative features extracted from clinical imaging. However, its reliability has been a concern, possibly due to its high-dimensional nature. This study aims to quantitatively investigate the impact [...] Read more.
Radiomics has the potential to aid prostate cancer (PC) diagnoses and prediction by analyzing and modeling quantitative features extracted from clinical imaging. However, its reliability has been a concern, possibly due to its high-dimensional nature. This study aims to quantitatively investigate the impact of randomly generated irrelevant features on MRI radiomics feature selection, modeling, and performance by progressively adding randomly generated features. Two multiparametric-MRI radiomics PC datasets were used (dataset 1 (n = 260), dataset 2 (n = 100)). The endpoint was to differentiate pathology-confirmed clinically significant (Gleason score (GS) ≥ 7) from insignificant (GS < 7) PC. Random features were generated at 12 levels with a 10% increment from 0% to 100% and an additional 5%. Three feature selection algorithms and two classifiers were used to build the models. The area under the curve and accuracy were used to evaluate the model’s performance. Feature importance was calculated to assess features’ contributions to the models. The metrics of each model were compared using an ANOVA test with a Bonferroni correction. A slight tendency to select more random features with the increasing number of random features introduced to the datasets was observed. However, the performance of the radiomics-built models was not significantly affected, which was partially due to the higher contribution of radiomics features toward the models compared to the random features. These reliability effects also vary among datasets. In conclusion, while the inclusion of additional random features may still slightly impact the performance of the feature selection, it may not have a substantial impact on the MRI radiomics model performance. Full article
Show Figures

Figure 1

17 pages, 4365 KiB  
Article
Joint Cancer Segmentation and PI-RADS Classification on Multiparametric MRI Using MiniSegCaps Network
by Wenting Jiang, Yingying Lin, Varut Vardhanabhuti, Yanzhen Ming and Peng Cao
Diagnostics 2023, 13(4), 615; https://doi.org/10.3390/diagnostics13040615 - 7 Feb 2023
Cited by 2 | Viewed by 2140
Abstract
MRI is the primary imaging approach for diagnosing prostate cancer. Prostate Imaging Reporting and Data System (PI-RADS) on multiparametric MRI (mpMRI) provides fundamental MRI interpretation guidelines but suffers from inter-reader variability. Deep learning networks show great promise in automatic lesion segmentation and classification, [...] Read more.
MRI is the primary imaging approach for diagnosing prostate cancer. Prostate Imaging Reporting and Data System (PI-RADS) on multiparametric MRI (mpMRI) provides fundamental MRI interpretation guidelines but suffers from inter-reader variability. Deep learning networks show great promise in automatic lesion segmentation and classification, which help to ease the burden on radiologists and reduce inter-reader variability. In this study, we proposed a novel multi-branch network, MiniSegCaps, for prostate cancer segmentation and PI-RADS classification on mpMRI. MiniSeg branch outputted the segmentation in conjunction with PI-RADS prediction, guided by the attention map from the CapsuleNet. CapsuleNet branch exploited the relative spatial information of prostate cancer to anatomical structures, such as the zonal location of the lesion, which also reduced the sample size requirement in training due to its equivariance properties. In addition, a gated recurrent unit (GRU) is adopted to exploit spatial knowledge across slices, improving through-plane consistency. Based on the clinical reports, we established a prostate mpMRI database from 462 patients paired with radiologically estimated annotations. MiniSegCaps was trained and evaluated with fivefold cross-validation. On 93 testing cases, our model achieved a 0.712 dice coefficient on lesion segmentation, 89.18% accuracy, and 92.52% sensitivity on PI-RADS classification (PI-RADS ≥ 4) in patient-level evaluation, significantly outperforming existing methods. In addition, a graphical user interface (GUI) integrated into the clinical workflow can automatically produce diagnosis reports based on the results from MiniSegCaps. Full article
Show Figures

Figure 1

Back to TopTop